Clinical Trial Site

Groningen 9713 GZ

4 studies enrolling now · 11 studies all time

What they study most

ANCA-Associated Vasculitis, ATTR Amyloidosis, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Early-Onset Alzheimer Disease, Familial Amyloid Polyneuropathies, Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy, TTR-mediated Amyloidosis

Studies at this site

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD — Recruiting now
• Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program — Recruiting now
• ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) — Recruiting now
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) — Completed
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Enrolling by invitation
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) — Completed
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis — Completed
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed